ORIC Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 07, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of

GlobeNewswireJun 7 16:30 ET

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of

GlobeNewswireMay 29 16:30 ET

Cantor Fitzgerald Reiterates Overweight on ORIC Pharmaceuticals

Cantor Fitzgerald analyst Prakhar Agrawal reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight.

BenzingaMay 28 09:13 ET

We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining exploration companies often lose money for years before finding success with a ne

Simply Wall StMay 8 08:47 ET

Buy Rating on Oric Pharmaceuticals Amidst Strong Financials and Promising Clinical Pipeline

TipRanksMay 8 06:27 ET

Analysts Offer Insights on Healthcare Companies: Ardelyx (ARDX), Oric Pharmaceuticals (ORIC) and Cellectis SA (CLLS)

TipRanksMay 8 00:50 ET